Last10K.com

Cortex Pharmaceuticals Inc (RSPI) SEC Filing 10-K Annual report for the fiscal year ending Monday, December 31, 2012

SEC Filings

RSPI Registration of Securities

Respirerx Pharmaceuticals Inc.

CIK: 849636 Ticker: RSPI
Document and Entity Information (USD $)
12 Months Ended
Dec. 31, 2012
Jun. 30, 2012
Document And Entity Information    
Entity Registrant Name CORTEX PHARMACEUTICALS INC/DE/  
Entity Central Index Key 0000849636  
Document Type 10-K  
Document Period End Date Dec. 31, 2012  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Is Entity a Well-known Seasoned Issuer? No  
Is Entity a Voluntary Filer? No  
Is Entity's Reporting Status Current? No  
Entity Filer Category Smaller Reporting Company  
Entity Public Float   $ 5,300,000
Entity Common Stock, Shares Outstanding 144,041,556  
Document Fiscal Period Focus FY  
Document Fiscal Year Focus 2012  

View differences made from one year to another to evaluate Respirerx Pharmaceuticals Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Respirerx Pharmaceuticals Inc..

Continue

Assess how Respirerx Pharmaceuticals Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Respirerx Pharmaceuticals Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2014 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations
Consolidated Statements Of Operations (parenthetical)
Consolidated Statements Of Stockholders' Equity (deficiency)
Commitments And Contingencies
Commitments And Contingencies (details Narrative)
Furniture, Equipment And Leasehold Improvements (tables)
Furniture, Equipment And Leasehold Improvements - Schedule Of Furniture, Equipment And Leasehold Improvements (details)
Furniture, Equipment And Leashold Improvements
Furniture, Equipment And Leashold Improvements (details Narrative)
Impairment And Termination Of University Of Illinois License Agreement
Impairment And Termination Of University Of Illinois License Agreement (details Narrative)
Income Taxes
Income Taxes (details Narrative)
Income Taxes (tables)
Income Taxes - Reconciliation Of Income Tax Rate Federal Statutory Rate And Effective Tax Rate (details)
Income Taxes - Schedule Of Deferred Tax Assets (details)
Merger With Pier Pharmaceuticals (tables)
Merger With Pier Pharmaceuticals Inc (details Narrative)
Merger With Pier Pharmaceuticals, Inc
Merger With Pier Pharmaceuticals, Inc - Summary Of Fair Value Of Assets Acquired And Liabilities Assumed (details)
Merger With Pier Pharmaceuticals, Inc - Summary Of Merger-related Costs (details)
Merger With Pier Pharmaceuticals, Inc - Summary Of Pro Forma Information Regarding Results Of Operations (details)
Note Payable To Related Party
Note Payable To Related Party (details Narrative)
Note Payable To Related Party - Summary Of Note Payable (details)
Notes Payable To Related Party (tables)
Organization And Business Operations
Organization And Business Operations (details Narrative)
Project Advance
Project Advance (details Narrative)
Related Party Transactions
Related Party Transactions (details Narrative)
Stockholder's Equity (details Narrative)
Stockholder's Equity - Schedule Of Common Stock Warrants Outstanding (details)
Stockholder's Equity - Schedule Of Stock Options Activity (details)
Stockholder's Equity - Schedule Of Stock Options Outstanding (details)
Stockholder's Equity - Schedule Of Warrants Activity (details)
Stockholders' Equity
Stockholders' Equity (tables)
Subsequent Events
Subsequent Events (details Narrative)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (details Narrative)
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (tables)
Summary Of Significant Accounting Policies - Summary Of Fair Value Option Award Using Black Scholes Pricing Model (details)
Summary Of Significant Accounting Policies - Summary Of Outstanding Securities Effect Of Anti Dilutive (details)
Ticker: RSPI
CIK: 849636
Form Type: 10-K Annual Report
Accession Number: 0001493152-14-003313
Submitted to the SEC: Tue Oct 14 2014 8:34:04 AM EST
Accepted by the SEC: Tue Oct 14 2014
Period: Monday, December 31, 2012
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/rspi/0001493152-14-003313.htm